Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)